Exocrine Pancreatic Insufficiency Market Size & Growth Forecast 2027–2036, By Segments (Therapy, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to content
Market Size and Growth Outlook
Exocrine Pancreatic Insufficiency Market size was more than USD 3.77 billion in 2026 and is set to grow at a 6.03% CAGR between 2027 and 2036, attaining USD 6.77 billion by 2036. The industry revenue for 2027 is estimated at USD 3.98 billion.
Get more details on this report
Request Free Sample ReportExocrine Pancreatic Insufficiency Market Intelligence Snapshot
Regional Market Dynamics
- North America leads through established diagnosis pathways, strong physician awareness, specialist care access, and structured follow-up that supports consistent pancreatic enzyme replacement therapy use.
- Asia Pacific is expected to expand at a 7.57% CAGR as improving diagnostics, broader gastroenterology access, and formalized treatment pathways bring more previously underdiagnosed patients into care.
Segment Momentum
- Pancreatic Enzyme Replacement Therapy is the largest and fastest-growing segment because it directly addresses digestive enzyme deficiency and supports long-term symptom control through consistent therapy use.
- Retail Pharmacies are growing fastest by providing convenient refill access for patients receiving long-term enzyme replacement therapy, supporting routine outpatient treatment continuation beyond hospital care.
Market Expansion Drivers
- Rising chronic pancreatitis incidence increasing demand for enzyme replacement therapies and diagnostics.
- Growing diabetes prevalence strengthening identification and treatment of associated pancreatic insufficiency cases.
- Advancements in diagnostic technologies improving early detection and long-term management of EPI patients.
Leading Market Participants
- Prominent companies in the exocrine pancreatic insufficiency market include AbbVie Inc. (United States), AstraZeneca PLC (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (United States), Bayer AG (Germany), Janssen Pharmaceuticals NV (Belgium), Abbott Laboratories (United States), Sun Pharmaceutical Industries Limited (India), Cipla Limited (India), Nestlé Health Science S.A. (Switzerland).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.77 billion
- 2027 Estimated Market Size: USD 3.98 billion.
- Projected Market Size: USD 6.77 billion by 2036
- Growth Forecast: 6.03% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Pancreatic Enzyme Replacement Therapy (Therapy) | Hospital Pharmacy (Distribution Channel)
- Emerging Opportunity Segment: Pancreatic Enzyme Replacement Therapy (Therapy) | Retail Pharmacy (Distribution Channel)
Market Growth Drivers and Industry Trends
Rising chronic pancreatitis incidence increasing demand for enzyme replacement therapies and diagnostics
The increasing burden of chronic pancreatitis will propel the exocrine pancreatic insufficiency market as progressive pancreatic damage can impair digestive enzyme production and contribute to nutritional and gastrointestinal complications. Greater recognition of pancreatic insufficiency among individuals with chronic pancreatic disease is encouraging the use of diagnostic evaluations and enzyme replacement therapies to address impaired digestion. Treatment demand is further supported by the need for sustained management of symptoms and nutritional deficiencies, with pancreatic enzyme replacement forming an important component of care for patients with inadequate exocrine function.
Growing diabetes prevalence strengthening identification and treatment of associated pancreatic insufficiency cases
A growing diabetes burden is supporting the exocrine pancreatic insufficiency market by increasing clinical attention toward pancreatic dysfunction among patients with diabetes and related metabolic complications. Changes in pancreatic structure and function can occur in association with diabetes, creating a need for appropriate evaluation when patients experience unexplained digestive symptoms or nutritional problems. Greater awareness among healthcare professionals of the potential relationship between metabolic disorders and impaired pancreatic exocrine function can encourage diagnostic assessment and appropriate enzyme-based management.
Advancements in diagnostic technologies improving early detection and long-term management of EPI patients
Technological improvements in pancreatic function assessment are expanding the exocrine pancreatic insufficiency market by making disease identification and monitoring more accessible and clinically informative. Enhanced diagnostic approaches can help healthcare professionals evaluate pancreatic enzyme insufficiency when symptoms overlap with other gastrointestinal disorders, supporting more timely intervention. Improved monitoring also allows treatment response and nutritional status to be assessed over time, helping clinicians refine management strategies for patients with persistent or progressive exocrine dysfunction.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising chronic pancreatitis incidence increasing demand for enzyme replacement therapies and diagnostics | 1.90% | High | North America, Europe, Asia Pacific | High | Near Term |
| Growing diabetes prevalence strengthening identification and treatment of associated pancreatic insufficiency cases | 1.70% | Moderate | Asia Pacific, North America | Medium | Mid Term |
| Advancements in diagnostic technologies improving early detection and long-term management of EPI patients | 1.40% | High | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the exocrine pancreatic insufficiency market, North America represented the largest regional market in 2026, benefiting from well-developed healthcare systems, greater disease awareness, and established access to diagnostic testing and enzyme replacement therapies. The region's strong network of gastroenterology specialists supports the identification and management of pancreatic disorders, while improved recognition of conditions associated with impaired pancreatic function is encouraging more patients to seek appropriate treatment. Growing emphasis on comprehensive management of chronic digestive disorders is further supporting demand for therapeutic interventions and nutritional care. Continued improvements in diagnostic practices and patient monitoring are also strengthening the regional market environment.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth, supported by expanding healthcare infrastructure, improving awareness of pancreatic and digestive disorders, and increasing access to specialized medical services. Healthcare providers are becoming better equipped to identify underlying conditions that can contribute to exocrine pancreatic insufficiency, creating opportunities for earlier intervention and ongoing disease management. Rising healthcare spending and broader availability of modern diagnostic and treatment options are improving access across emerging healthcare markets. In parallel, greater attention to nutritional management and chronic disease care is encouraging the adoption of therapies designed to address digestive and absorption-related complications.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Guideline-Based CareGermany prioritizes standardized diagnostic pathways and evidence-based treatment protocols for exocrine pancreatic insufficiency. Collaboration between hospitals and outpatient specialists encourages consistent use of enzyme replacement therapy and long-term nutritional management.
France 🇫🇷
Nutritional Care IntegrationFrance integrates nutritional assessment with pharmacological management for patients with exocrine pancreatic insufficiency. Multidisciplinary care models encourage coordinated treatment approaches that improve digestive health and patient adherence.
Italy 🇮🇹
Clinical Management RefinementItaly focuses on improving recognition of exocrine pancreatic insufficiency among patients with chronic gastrointestinal and pancreatic disorders. Greater emphasis on optimized enzyme dosing and follow-up supports more consistent therapeutic outcomes.
Japan 🇯🇵
Aging Patient FocusJapan addresses exocrine pancreatic insufficiency with attention to its aging population and increasing prevalence of chronic pancreatic diseases. Healthcare providers focus on nutritional optimization and personalized enzyme replacement strategies to improve patient quality of life.
South Korea 🇰🇷
Specialist Treatment ExpansionSouth Korea is strengthening specialist-led diagnosis and treatment of exocrine pancreatic insufficiency within advanced healthcare facilities. Greater clinical awareness and improved access to pancreatic enzyme therapies support more comprehensive disease management.
United States 🇺🇸
Advanced Diagnostic AdoptionThe U.S. emphasizes earlier diagnosis of exocrine pancreatic insufficiency through specialist gastroenterology networks and improved clinical awareness. Growing use of pancreatic enzyme replacement therapy is supported by patient education initiatives and integrated management of chronic pancreatic disorders.
Exocrine Pancreatic Insufficiency Market Share (%), by Therapy, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTherapy Segment Analysis: Pancreatic Enzyme Replacement Therapy (Largest & Fastest-Growing Segment)
Pancreatic enzyme replacement therapy dominated the exocrine pancreatic insufficiency market in 2026 and is also the fastest-growing therapy segment because it directly addresses the digestive enzyme deficiency associated with the condition. Enzyme replacement helps improve the digestion and absorption of nutrients, making it a fundamental component of symptom management and nutritional support. Greater recognition of exocrine pancreatic insufficiency across underlying pancreatic disorders, together with increasing emphasis on appropriate enzyme dosing and long-term disease management, is strengthening adoption of this therapy.
Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)
Hospital pharmacy held the largest share of the exocrine pancreatic insufficiency market in 2026, reflecting the close connection between diagnosis, specialist treatment, and medication management for patients with underlying pancreatic conditions. Hospitals provide access to gastroenterology and other specialist services, enabling therapies to be prescribed and monitored within coordinated care pathways. The need for clinical assessment and management of nutritional and digestive complications continues to support hospital pharmacies as a major distribution channel.
Retail pharmacy is advancing at the fastest rate as long-term management of exocrine pancreatic insufficiency increasingly creates demand for convenient access to enzyme replacement therapies and medication refills. Community-based pharmacies can improve accessibility for patients who have transitioned from specialist or hospital care to ongoing treatment. Greater emphasis on outpatient disease management and convenient medication availability is supporting the expansion of retail pharmacy distribution.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Therapy | Pancreatic Enzyme Replacement Therapy, Natural Therapy | Pancreatic Enzyme Replacement Therapy | Pancreatic Enzyme Replacement Therapy |
| Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Others | Hospital Pharmacy | Retail Pharmacy |
Competitive Landscape and Market Positioning
Prominent players in the exocrine pancreatic insufficiency market:
1. AbbVie Inc. (United States)
2. AstraZeneca PLC (United Kingdom)
3. Takeda Pharmaceutical Company Limited (Japan)
4. Pfizer Inc. (United States)
5. Bayer AG (Germany)
6. Janssen Pharmaceuticals NV (Belgium)
7. Abbott Laboratories (United States)
8. Sun Pharmaceutical Industries Limited (India)
9. Cipla Limited (India)
10. Nestlé Health Science S.A. (Switzerland)
The exocrine pancreatic insufficiency market is progressing through improved enzyme replacement innovations and formulation optimization. Research-driven initiatives are enhancing treatment efficiency and digestive absorption outcomes. New therapeutic options are being introduced to address varied patient needs and severity levels. Technology integration in drug formulation is also supporting improved stability and delivery performance.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. (United States) | |||||||
| AstraZeneca PLC (United Kingdom) | |||||||
| Takeda Pharmaceutical Company Limited (Japan) | |||||||
| Pfizer Inc. (United States) | |||||||
| Bayer AG (Germany) | |||||||
| Janssen Pharmaceuticals NV (Belgium) | |||||||
| Abbott Laboratories (United States) | |||||||
| Sun Pharmaceutical Industries Limited (India) | |||||||
| Cipla Limited (India) | |||||||
| Nestlé Health Science S.A. (Switzerland). |
Industry Development / News
| Company Name | Date | Key Development |
|---|---|---|
| Anagram Therapeutics | May-26 | Anagram Therapeutics secured a USD 250 million investment from Blackstone Life Sciences to advance ANG003, a novel oral recombinant enzyme replacement therapy. The funding supports clinical development, regulatory approval, and commercialization efforts targeting exocrine pancreatic insufficiency across cystic fibrosis, pancreatic cancer, and related conditions. |
| Blackstone Life Sciences | May-26 | Blackstone Life Sciences committed USD 250 million to Anagram Therapeutics to support development and commercialization of next-generation oral enzyme replacement therapies. The investment strengthens pipeline advancement in exocrine pancreatic insufficiency treatment and supports future market entry of novel therapeutic solutions. |
| Alcresta Therapeutics | Apr-25 | Alcresta Therapeutics enrolled the first patient in an investigator-initiated clinical trial at Massachusetts General Hospital evaluating RELiZORB for exocrine pancreatic insufficiency in tube-fed pancreatitis patients. The study supports clinical validation of enzyme-based nutritional support solutions for severe pancreatic dysfunction. |
| Horizon Therapeutics | Apr-25 | Horizon Therapeutics received FDA approval for Uplizna (inebilizumab-cdon) for IgG4-related disease, a condition linked to autoimmune pancreatitis. The approval introduces a targeted immune therapy approach relevant to pancreatic disease management and supports expansion of treatment options in immune-mediated pancreatic disorders. |
| Adalvo | Mar-25 | Adalvo prepared for the European launch of pancreatin delayed-release capsules, a key enzyme replacement therapy for exocrine pancreatic insufficiency. The initiative aims to expand access to enzyme-based treatments and strengthen its position in the gastrointestinal therapeutics market across Europe. |
| AbbVie | 2025 | AbbVie presented updated gastrointestinal research data, with continued support for studies in digestive disorders including exocrine pancreatic insufficiency. The activity reflects ongoing engagement in advancing therapeutic understanding across broader gastrointestinal disease areas relevant to enzyme deficiency conditions. |
| Nestlé S.A. | Jan-20 | Nestlé S.A. entered an asset purchase agreement with Allergan to acquire the gastrointestinal drug Zenpep. The acquisition strengthened Nestlé’s medical nutrition portfolio and expanded its presence in enzyme-based therapies used in digestive disorders including exocrine pancreatic insufficiency. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Exocrine Pancreatic Insufficiency Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Etiology | Chronic Pancreatitis, Cystic Fibrosis, Pancreatic Cancer, Pancreatic Surgery, Other Causes |
| Patient Demographics | Pediatric Patients, Adult Patients, Geriatric Patients |
| Treatment Line | First-Line Treatment, Second-Line Treatment, Refractory or Salvage Treatment |
Exocrine Pancreatic Insufficiency Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Patient Journey and Diagnostic Delay Assessment |
|
| Pancreatic Enzyme Replacement Therapy Adoption Analysis |
|
| High-Risk Patient Identification and Referral Landscape |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much is the exocrine pancreatic insufficiency market worth?
How is the exocrine pancreatic insufficiency industry expected to grow over the next 10 years?
How is rising chronic pancreatitis incidence shaping demand for pancreatic enzyme replacement therapy?
What role is diabetes prevalence playing in improving identification and treatment of exocrine pancreatic insufficiency?
Why is Pancreatic Enzyme Replacement Therapy the leading treatment in the exocrine pancreatic insufficiency market?
Why are Retail Pharmacies the fastest-growing distribution channel in the exocrine pancreatic insufficiency market?
Why is North America the leading regional market for exocrine pancreatic insufficiency?
What factors are accelerating growth in the Asia Pacific exocrine pancreatic insufficiency market?
What are the key competitors in the exocrine pancreatic insufficiency landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook